<DOC>
	<DOCNO>NCT02062203</DOCNO>
	<brief_summary>The main purpose study evaluate effect single oral therapeutic supratherapeutic dos AKB-6548 QT interval .</brief_summary>
	<brief_title>Effect AKB-6548 Cardiac Repolarization Intervals Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Key Healthy , nonsmoking male female , 18 55 year age , inclusive BMI 18.0 32.0 kg/m2 , inclusive non clinically significant 12lead ECG heart rate 45 90 beat per minute , inclusive mean systolic blood pressure &lt; 141 mmHg mean diastolic blood pressure &lt; 90 mmHg Key history presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , GI , endocrine , immunologic , dermatologic , neurologic , psychiatric disease history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia , torsades de pointes , structural heart disease , family history Long QT syndrome significant abnormality liver function test history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug history Gilbert 's Syndrome positive hepatitis panel seizure disorder receive antiepilepsy medication seizure disorder acute chronic condition , opinion Investigator , may pose safety risk subject study would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Akebia</keyword>
	<keyword>QT interval</keyword>
	<keyword>TQT</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>safety</keyword>
</DOC>